Scope and claims analysis for U.S. Patent 12,472,174 (agitation in Alzheimer’s with bupropion-dextromethorphan and alcohol minimization)
U.S. Patent 12,472,174 claims a staged, oral, two-drug regimen using a bupropion–dextromethorphan combination to treat agitation associated with Alzheimer’s disease in patients who consume alcohol, with a central limitation that alcohol intake is minimized but not abruptly discontinued. The independent method claim is tightly framed around: (i) a two-phase titration (once-daily for 1 week, then twice-daily for 1 week, then a second dosage form twice-daily for at least 1 week), (ii) specific strengths (first dosage: 105 mg bupropion HCl + 30 mg dextromethorphan HBr; second dosage: 105 mg bupropion HCl + 45 mg dextromethorphan HBr), and (iii) alcohol-management behavior during treatment. Dependent claims add formulation components and release characteristics (extended release bupropion; immediate release dextromethorphan), plus optional excipients (e.g., colloidal silicon dioxide, crospovidone, carbomer polymer, L-cysteine HCl monohydrate, etc.) and gender/serving thresholds for post-administration alcohol consumption.
What is U.S. Patent 12,472,174 claiming in plain terms?
Answer: It claims a method of treating agitation associated with Alzheimer’s disease using a bupropion + dextromethorphan regimen in patients who drink alcohol, where the method includes minimizing alcohol consumption without abruptly stopping, using two specifically defined dosage forms in a titration schedule.
Independent claim 1: the full technical structure
Claim 1 is a combined clinical + dosing + formulation + alcohol-behavior method claim with these core elements:
-
Patient population
- A human patient with agitation associated with Alzheimer’s disease who is consuming alcohol.
-
Treatment includes an alcohol-management instruction
- Minimizing but not abruptly discontinuing alcohol consumption.
-
Staged dosing regimen
- First dosage form:
- Once daily for one week
- then twice daily for one week
- Then second dosage form:
- Twice daily for at least one week
- The regimen is explicitly tied to treating agitation.
-
Specific active strength definitions
- First dosage form comprises:
- 105 mg bupropion hydrochloride
- 30 mg dextromethorphan hydrobromide
- and a polymer
- Second dosage form comprises:
- 105 mg bupropion hydrochloride
- 45 mg dextromethorphan hydrobromide
-
Polymer present in the first dosage form (as claimed)
- Claim 1 says the first dosage form includes a polymer; it later recurs that the polymer limitation is part of “the first dosage form comprises… and a polymer.”
- Dependent claim 14 specifies the polymer as carbomer homopolymer.
Claim 1 is not a “bupropion + dextromethorphan for agitation” claim only. The claim scope is narrowed by the alcohol-minimization behavioral instruction and the two-formulation, two-strength titration schedule.
Dependent claims 2–3: sex-specific alcohol serving limits
- Claim 2: adult male; after administration of either dosage form, ≤ 2 servings/day
- Claim 3: adult female; after administration of either dosage form, ≤ 1 serving/day
These claims further tighten enforceability by adding measurable post-dosing behavior thresholds.
Dependent claims 4–13 and 15: formulation-excipient permutations
Claims 4–13 and 15 add multiple excipient limitations to “the first or second dosage form,” including:
- Colloidal silicon dioxide (claim 4; also in claim 15 composite list)
- Crospovidone (claim 5)
- Glyceryl monocaprylocaprate (claim 6)
- L-cysteine hydrochloride monohydrate (claim 7)
- Magnesium stearate (claim 8)
- Microcrystalline cellulose (claim 9)
- Polyvinyl alcohol (claim 10)
- Sodium lauryl sulfate (claim 11)
- Stearic acid (claim 12)
- Titanium dioxide (claim 13)
- Iron oxides: red and yellow (in claim 15 list)
- Talc (in claim 15 list)
Claim 15 is a “laundry list” composite limitation that includes multiple excipients (and “or a combination thereof”), creating scope that can be asserted against formulations matching one or more of the listed components depending on claim construction of “or a combination thereof.”
Dependent claims 16–24: specificity on strengths and release types
- Claim 16: second dosage form has 105 mg bupropion HCl
- Claim 17 / 18: second dosage form has 45 mg dextromethorphan HBr
- Claim 19: dextromethorphan is immediate release
- Claim 20: bupropion is extended release
- Claim 21: method is oral administration
- Claim 22: reduced alcohol-dosing effects vs administering bupropion alone
- Claims 23–24: first dosage form includes 30 mg dextromethorphan HBr (and repeats)
These dependent claims create multiple fallback positions if an accused method/dosage form misses certain components.
What part of the claim is most likely to drive claim construction and infringement risk?
Answer: The “minimizing but not abruptly discontinuing alcohol consumption” limitation and the two-phase titration schedule with exact strengths are the most constraining elements of claim 1.
Alcohol behavior limitation: “minimizing but not abrupt discontinuation”
Claim 1 ties treatment to a specific counseling/behavioral management instruction. In practical enforcement, this becomes a question of:
- Whether the accused method instructs clinicians/patients to minimize alcohol intake; and
- Whether it prohibits or avoids abrupt discontinuation.
Because the limitation is embedded in the method, it can narrow infringement even where the dose strengths match.
Exact dosing schedule + two dosage forms
Claim 1 requires:
- First dosage form:
- 1 week once daily
- then 1 week twice daily
- Then:
- second dosage form at least 1 week twice daily
Many real-world regimens for neuropsychiatric symptoms include loading/titration, but the combination of exact timing and exact dose strengths is a claim-strengthening feature.
Drug strengths: the “105/30” then “105/45” structure
The independent claim’s dosage form strength definitions are explicit:
- First dosage: 105 mg bupropion HCl + 30 mg dextromethorphan HBr
- Second dosage: 105 mg bupropion HCl + 45 mg dextromethorphan HBr
This creates a relatively direct line of infringement analysis for dosage matching.
Which prior art and existing drug products could be implicated?
Answer: The claim is centered on bupropion + dextromethorphan and a very specific use case (Alzheimer’s agitation) plus alcohol minimization.
Given only the text of the claims, the patent landscape assessment for “which prior art” or “which earlier patents” cannot be completed to a defensible level of detail without the actual patent record (publication number, filing priority, prosecution history, and the cited references). The claim text alone does not identify:
- the assignee,
- the earliest priority date,
- the technology origin (whether it is derived from a known combination product),
- or the examiner’s cited documents.
So an accurate “scope vs prior art” mapping by document number and dates is not possible from the information provided.
How broad is the claim set: composition vs method vs formulation
Answer: It is a method-of-treatment claim with embedded dosage-form definitions, not a standalone composition claim. Scope varies by dependent claim fallback positions.
Core breadth (claim 1)
- Covers any “polymer” formulation in the first dosage form (unless constrained by dependent claims).
- “Bupropion hydrochloride” and “dextromethorphan hydrobromide” are defined with flexibility to “molar equivalent” salt forms or free base in claim 1 language.
- Still requires exact mg amounts in the claim recited structure, and the dosage schedule.
Dependent claim narrowing
- Claims 19–20 restrict release forms (immediate release dextromethorphan; extended release bupropion).
- Claims 4–13/15 restrict formulation excipients.
- Claims 2–3 restrict alcohol intake by gender and serving count.
In infringement posture, claim 1 is broader than the excipient-specific and release-specific dependent claims, but still constrained by the alcohol-behavior limitation and the titration/strength schedule.
How many distinct infringement “routes” exist inside the claim set?
Answer: At least two major routes: one based on method elements (alcohol instruction + titration + strengths) and another based on formulation elements (immediate/extended release and excipient stack).
Route A: satisfy claim 1 elements
An accused method must include:
- Alzheimer’s agitation indication,
- patient consuming alcohol,
- alcohol minimization without abrupt discontinuation,
- staged dosing to reach 105 mg bupropion with 30 mg then 45 mg dextromethorphan with the schedule.
Route B: dependent-claim assertion (if route A is difficult)
If the accused regimen is close but not identical, the patent may still assert:
- immediate-release/extended-release requirements (claims 19–20),
- particular excipient inclusion (claims 4–13, 15),
- and post-administration alcohol serving caps by sex (claims 2–3).
Route C: reduction in alcohol dosing effects
Claim 22 introduces a comparative pharmacological property: reduced alcohol dosing effects versus bupropion alone with same dose regimen. If a challenger disputes performance data, that becomes evidentiary rather than purely structural. The claim text alone does not indicate how the reduction is measured.
What are the likely license and design-around options?
Answer: The strongest design-around levers are to avoid one of the three hard limitations: (i) the alcohol minimization without abrupt discontinuation instruction, (ii) the titration schedule and two dosage-form strength progression, or (iii) the specific release characteristics and/or dosage-form excipient set.
Formulation design-around (weaker if claim 1 is asserted)
- Changing excipients can avoid claims 4–13/15.
- Changing release profile can avoid claims 19–20.
But claim 1 still requires the polymer (unspecified type unless claim 14 applies) and the exact dose strengths and schedule.
Clinical-method design-around (potentially stronger)
- If the accused method instead uses abrupt discontinuation protocols or a different alcohol counseling standard, it can attempt to exit the “minimizing but not abruptly discontinuing” limitation.
- If the dosing schedule does not match the one-week once-daily then one-week twice-daily then at least one-week twice-daily second dosage-form progression, it can attempt to avoid claim 1.
Orange Book status, Paragraph IV risk, and generic/biosimilar landscape
Answer: Not determinable from the provided information.
The question asks for a detailed patent landscape for a specific U.S. patent, which normally requires:
- the related FDA NDA/ANDA reference (Orange Book listing),
- the drug product(s) and dosage forms mapped to the listed patents,
- and any known Paragraph IV filings, settlements, or at-risk launch dates.
Those elements are not supplied in the prompt and cannot be derived solely from the claim text.
Patent landscape map inside the claim (what to focus on in enforcement)
Even without the external record, the claim set suggests the patent’s likely litigation posture:
Patent scope hotspots to test in an infringement analysis
- Does the accused regimen use 105 mg bupropion with 30 mg then 45 mg dextromethorphan?
- Does the accused regimen follow the exact timing (once daily 1 week, twice daily 1 week, then second dosage twice daily at least 1 week)?
- Does the clinician/patient instruction meet “minimizing but not abruptly discontinuing” alcohol consumption?
- Does the accused product match immediate-release dextromethorphan and extended-release bupropion?
- Do the products match the defined or listed excipients (if fallback claims are pursued)?
- Are gender-specific alcohol serving caps (≤2 male, ≤1 female) followed or claimed?
Key Takeaways
- U.S. Patent 12,472,174 is a method-of-treatment claim for agitation associated with Alzheimer’s disease that explicitly incorporates alcohol-management counseling: minimize alcohol consumption without abrupt discontinuation.
- The claim scope is driven by a staged titration using two dosage forms with exact active strengths: 105 mg bupropion HCl + 30 mg dextromethorphan HBr first, followed by 105 mg bupropion HCl + 45 mg dextromethorphan HBr.
- Dependent claims narrow further with sex-specific alcohol serving limits, release profiles (immediate release dextromethorphan; extended release bupropion), and excipient stack options.
- A defensible “full patent landscape” (related patents, expiration chain, Orange Book mapping, and Paragraph IV litigation) cannot be produced from the claim text alone.
FAQs
1. What does the “minimizing but not abruptly discontinuing alcohol consumption” limitation cover?
It requires that the treatment method includes patient guidance to reduce alcohol intake while avoiding abrupt cessation.
2. What are the exact active strengths required in the first and second dosage forms?
First dosage form: 105 mg bupropion HCl + 30 mg dextromethorphan HBr; second dosage form: 105 mg bupropion HCl + 45 mg dextromethorphan HBr.
3. Does the patent require extended-release bupropion and immediate-release dextromethorphan?
Only if asserted via dependent claims: claim 20 (bupropion extended release) and claim 19 (dextromethorphan immediate release).
4. Can excipient changes avoid infringement?
They may avoid dependent claims directed to specific excipients, but they do not remove the core limitations in claim 1 (alcohol behavior + titration schedule + strengths).
5. Is this patent about formulation chemistry or primarily clinical method?
Primarily clinical method, with formulation/dosage-form characteristics embedded through the claimed dosage strengths and dependent excipient and release features.
References
No external sources were cited because the provided prompt contains the only patent text available for analysis.
